You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 138 No. 2, February 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Correspondence
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Compounding of Topical Cidofovir

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We would like to point out an error appearing in the article on topical cidofovir by Toro et al.1 In the "Solution" section, the first sentence reads, "Topical 3% cidofovir was compounded as follows: 15 g of cidofovir (75 mg/mL) was mixed with 22.5 g of a combination vehicle (Dermovan; Galderma Laboratory Inc, Fort Worth, Tex)."

Cidofovir (Vistide Injection; Gilead Sciences, Inc, Foster City, Calif) is supplied at a concentration of 75 mg/mL and packaged as 375 mg in a 5-mL single-unit glass vial. To add 15 g of cidofovir to the vehicle would require adding 200 mL of cidofovir solution. The resulting mixture would have a final concentration of 6.7%.

We believe that the amount of cidofovir listed in the article, 15 g, is incorrect, and instead should read 15 mL. Adding 15 mL of cidofovir solution (75 mg/mL) to 22.5 g of vehicle results in a total (cidofovir . . . [Full Text of this Article]







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.